Patients with Ankylosing Spondylitis Treatment by Golimumab: a Systematic Review and Meta-analysis

Overview

Journal Eur Spine J

Specialty Orthopedics

Date 2020 May 25

PMID 32447529

Citations 3

Authors

Jami Sayed Abdulla

Jiandang Shi

Brotendu Shekhar Roy

Zhou Zhanwen

Changhao Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS).

Methods: Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes.

Results: We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE.

Conclusions: Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.

Citing Articles

Role of HLA class I and II alleles in susceptibility to ankylosing spondylitis in Chinese Han.

Jiang Y, Liu Q, Kong X, Zhao M, Liu Y, Gao P J Clin Lab Anal. 2023; 37(17-18):e24964.

PMID: 37747092 PMC: 10623521. DOI: 10.1002/jcla.24964.

Golimumab Ameliorates Pancreatic Inflammatory Response in the Cerulein-Induced Acute Pancreatitis in Rats.

Kaplan M, Tanoglu A, Cakir Guney B, Yeniceri M, Cirak Z, Tastan Y Turk J Gastroenterol. 2022; 33(11):918-924.

PMID: 36262104 PMC: 9797786. DOI: 10.5152/tjg.2022.21456.

Effects of Different Drug Therapies and COVID-19 mRNA Vaccination on Semen Quality in a Man with Ankylosing Spondylitis: A Case Report.

Chatzimeletiou K, Fleva A, Sioga A, Georgiou I, Nikolopoulos T, Markopoulou M Medicina (Kaunas). 2022; 58(2).

PMID: 35208497 PMC: 8875133. DOI: 10.3390/medicina58020173.

References

Braun J, Deodhar A, Inman R, van der Heijde D, Mack M, Xu S . Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2011; 71(5):661-7. PMC: 3329230. DOI: 10.1136/ard.2011.154799. View

Deodhar A, Braun J, Inman R, van der Heijde D, Zhou Y, Xu S . Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2014; 74(4):757-61. PMC: 4392310. DOI: 10.1136/annrheumdis-2014-205862. View

Deodhar A, Reveille J, Harrison D, Kim L, Lo K, Leu J . Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. J Rheumatol. 2017; 45(3):341-348. DOI: 10.3899/jrheum.170487. View

Inman R, Davis Jr J, van der Heijde D, Diekman L, Sieper J, Kim S . Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008; 58(11):3402-12. DOI: 10.1002/art.23969. View

Kay J, Fleischmann R, Keystone E, Hsia E, Hsu B, Mack M . Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2013; 74(3):538-46. PMC: 4345908. DOI: 10.1136/annrheumdis-2013-204195. View

Kruger K, von Hinuber U, Meier F, Tian H, Bohm K, Jugl S . Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int. 2018; 38(11):2121-2131. DOI: 10.1007/s00296-018-4124-z. View

Ma H, Sun F, Zhang Y, Zhang H, Zhu J, Deng X . [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis]. Zhonghua Nei Ke Za Zhi. 2017; 56(12):935-939. DOI: 10.3760/cma.j.issn.0578-1426.2017.12.009. View

Sandra A, Fyler D . The effect of membrane phospholipid modification on insulin action in adipocytes from normal and streptozotocin-induced diabetic rats. Horm Metab Res. 1982; 14(12):638-41. DOI: 10.1055/s-2007-1019106. View

Berry G, Mathews W . Gastric lymphosarcoma and pseudolymphoma: reappraisal of 12 cases of gastric lymphosarcoma. Can Med Assoc J. 1967; 96(19):1312-6. PMC: 1922912. View

10.

van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany T . The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014; 41(6):1095-103. DOI: 10.3899/jrheum.131003. View

11.

Wang Y, Zheng G, Zhang Y, Song K, Song D, Zhang X . Proposal of a New Treatment-Oriented Classification System for Spinal Deformity in Ankylosing Spondylitis. Spine Deform. 2018; 6(4):366-372. DOI: 10.1016/j.jspd.2017.06.001. View

12.

Wronski J, Fiedor P . The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?. J Clin Pharmacol. 2018; 59(4):445-462. DOI: 10.1002/jcph.1348. View